Daily non-political popular news in brief.

Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators

How did a failed contraceptive become the first targeted therapy for the treatment of breast cancer? The transformation of tamoxifen, from cast-off to lifesaver, laid the foundation for a new class of therapeutics -- selective estrogen receptor modulators. V. Craig Jordan, a researcher at the Fox Chase Cancer Center in Philadelphia, Jordan reports on efforts to use the lessons from tamoxifen to develop new hormone receptor-related drugs for both women and men.

Read more »

Keywords: moving, beyond, tamoxifen, drug, discovery, future, selective, hormone, receptor, modulators, modulator

« Previous | Next »

Similar news on "Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators":

1. A new computational technique predicts side-effects of a major cancer drug
   11-27-2007 · EurekAlert!
   Researchers at the University of California San Diego have developed a novel computer technique to search for the side effects of major pharmaceuticals. The study, reported Nov. 30 in PLoS Computational Biology, relates to a class of drugs known as Select Estrogen Receptor Modulators, which includes tamoxifen, the most prescribed drug in the treatment of breast cancer.
   Similar news · Read more »
   
2. News Tips from ACS Chemical Biology
   10-31-2006 · EurekAlert!
   In this issue of ACS Chemical Biology, issue we learn about a new technique to study how proteins interact in the cell, we report on a small molecule that binds to a specific thyroid hormone receptor and controls its activity, and we learn how to enhance an antibiotic so that it can no longer be pumped out of a bacterial cell. Other highlights in this issue include finding peptide-based modulators of signaling G Proteins.
   Similar news · Read more »
   
3. New study demonstrates efficacy of Pfizer's Aromasin for early breast cancer
   12-15-2006 · EurekAlert!
   New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56 percent less likely to have a relapse of breast cancer than those who received placebo.
   Similar news · Read more »
   
4. Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
   01-31-2008 · EurekAlert!
   Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of The Lancet.
   Similar news · Read more »
   
5. Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
   01-31-2008 · EurekAlert!
   Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
   Similar news · Read more »
   
6. Researchers find docking sites for glucocorticoid receptor and Hsp90
   11-20-2006 · EurekAlert!
   University of Oregon researchers have identified protein interactions that regulate the response of cells to steroid hormones. The discovery, they say, could lead to new ways to boost the effectiveness and reduce undesired side effects of steroid-hormone treatments and cancer drugs.
   Similar news · Read more »
   
7. Why you remember names and ski slopes
   11-21-2007 · EurekAlert!
   Researchers at Northwestern University have discovered the brain protein kalirin-7 is critical for helping you learn and remember what you learned. Previous studies by other researchers found that kalirin levels are reduced in brains of people with diseases like Alzheimer's and schizophrenia. Thus, the discovery of kalirin's role in learning offers new insight into the pathophysiology of these disorders and makes it a new target for future drug therapy to treat or delay the progression of these diseases.
   Similar news · Read more »
   
8. Targeting nerve growth factor may cure liver cancer
   09-19-2007 · EurekAlert!
   Biologists led by Dr. Serafino from the National Research Council of Italy published their surprising discovery that NGF and its receptor were aberrantly expressed in the liver of the patients troubled with liver cirrhosis and/or hepatocellular carcinoma. These two molecules are not expressed in the liver of healthy people. Published in the Oct. 7 issue of the World Journal of gastroenterology, this article brings a bright future for devising a cure for HCC.
   Similar news · Read more »
   
9. Discovery in plants suggests entirely new approach to treating human cancers
   04-04-2007 · EurekAlert!
   For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone -- auxin -- interacts with its hormone receptor, called TIR1. Their report, on the cover of this week's issue of Nature, also may have important implications for the treatment of human disease, because TIR1 is similar to human enzymes that are known to be involved in cancer.
   Similar news · Read more »
   
10. Targeting nerve growth factor may cure liver cancer
    09-05-2007 · EurekAlert!
    Biologists led by Dr. Serafino from the National Research Council of Italy published their surprising discovery that NGF and its receptor were aberrantly expressed in the liver of the patients troubled with liver cirrhosis and/or hepatocellular carcinoma (HCC). These two molecules are not expressed in the liver of healthy people. Published in the October 7 issue of the World Journal of gastroenterology, this article brings a bright future for devising a cure for HCC.
    Similar news · Read more »